Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary
Bibliographic record
Abstract
Plain Language SummaryWhat is this summary about?This summary describes the results from an additional (or post-hoc) analysis of the ARASENS trial in which researchers studied the impact of prostate-specific antigen (PSA) response on treatment outcomes, including how long patients lived, in metastatic hormone-sensitive prostate cancer (mHSPC). mHSPC is a form of prostate cancer that has spread to other parts of the body but can be treated with hormone therapy.The ARASENS trial included 1,305 patients with mHSPC. In this trial, combining darolutamide with two other medications called androgen deprivation therapy (ADT) and docetaxel increased the chances of survival and lowered the risk of death by 32.5%. The percentage of patients reporting medical problems, also called adverse events, was similar to those who received placebo with ADT and docetaxel.What were the PSA results?More than double the patients who received darolutamide, ADT, and docetaxel achieved a deep PSA response compared with those who received placebo, ADT, and docetaxel.Patients who received darolutamide with ADT and docetaxel had more time before their PSA levels increased (durable PSA response) compared with those who received a placebo with ADT and docetaxel.Compared with patients who did not achieve a deep PSA response in the darolutamide group, patients who had a deep PSA response lived longer, had more time before their cancer stopped responding to hormone treatment such as ADT, and had more time before their PSA levels increased.What do these results mean?These results show an important link between a deep PSA response and improved treatment outcomes. They also highlight the importance of monitoring PSA levels and aiming to achieve a deep PSA response at any time during treatment for mHSPC. These findings suggest that triple therapy of darolutamide plus ADT and docetaxel could be considered for all patients with mHSPC, including those with low-volume disease.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".